Publication:
Sequencing novel agents in the treatment of classical Hodgkin lymphoma

dc.contributor.coauthorOzbalak, Murat
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:30:57Z
dc.date.issued2023
dc.description.abstractIntroductionClassical Hodgkin lymphoma (cHL) is a curable disease, with durable remission achieved in about 80% of patients following first-line treatment. Three new drugs were introduced to the daily use in cHL: brentuximab vedotin (BV), nivolumab, and pembrolizumab. All three drugs were initially approved for the treatment of relapsed/refractory cHL (RRHL) and with their promising outcomes, they are now incorporated in different stages of the treatment.Areas coveredWe performed a literature search using PubMed on all cHL studies investigating BV and CPIs within the past 10 years. We analyzed literature to presume the sequencing of these novel agents.Expert opinionAddition of BV or nivolumab to AVD backbone in the frontline setting showed promising activity in advanced stage cHL. BV and CPIs combined with chemotherapy in the second-line treatment of cHL are evaluated in phase 2 studies and comparable results are reported. The results of BrECADD, with good efficacy and toxicity profile, should be followed. Pembrolizumab was shown to be more effective in RRHL compared to BV in patients who have relapsed post-ASCT or ineligible for ASCT. BV is used in post-ASCT maintenance in high-risk cases, although its role will be questioned as it is increasingly used in the frontline treatment.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue12
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume16
dc.identifier.doi10.1080/17474086.2023.2276212
dc.identifier.eissn1747-4094
dc.identifier.issn1747-4086
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85176916714
dc.identifier.urihttps://doi.org/10.1080/17474086.2023.2276212
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26157
dc.identifier.wos1102961700001
dc.keywordsClassical Hodgkin lymphoma
dc.keywordsBrentuximab vedotin
dc.keywordsCheckpoint inhibitor
dc.keywordsNivolumab
dc.keywordsPembrolizumab
dc.keywordsAnti-PD1 antibody
dc.language.isoeng
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofExpert Review of Hematology
dc.subjectHematology
dc.titleSequencing novel agents in the treatment of classical Hodgkin lymphoma
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files